Limitations of intravenous human bone marrow CD133+cell grafts in stroke rats

被引：37

作者：

Borlongan, CV

Evans, A

Yu, GL

Hess, DC

机构：

[1] Med Coll Georgia, Dept Neurol, Augusta, GA 30912 USA

[2] Med Coll Georgia, Inst Mol Med & Genet, Augusta, GA 30912 USA

[3] Augusta VA Med Ctr, Res & Affiliat Serv Line, Augusta, GA 30912 USA

来源：

BRAIN RESEARCH | 2005年 / 1048卷 / 1-2期

关键词：

xenografts; stem cells; cerebral ischemia; graft survival; motor behavior; neurological deficits;

D O I：

10.1016/j.brainres.2005.04.087

中图分类号：

Q189 [神经科学];

学科分类号：

071006 ;

摘要：

We examined the effects of timing and routes of transplantation on survival and functional benefits of human bone-marrow-derived CD133+ cells in experimentally stroke Sprague-Dawley rats. At day 7 post-stroke, both immediate and delayed intracerebral transplantation resulted in similar graft survival (7%) that was localized within the original transplant site and reduction of motor (27%) and neurological (40%) deficits. In contrast, graft survival (0.0 1 -0.04%) was only detected in delayed intravenous transplantation, characterized by cell migration throughout the ipsilateral stroke hemisphere. Behavioral improvement, however, was limited to neurological response and only apparent in immediate intravenous transplantation. Reduction of cerebral infarct (25%) was only noted in intracerebral transplantation. Intravenous transplantation requires optimization for improved therapeutic outcome of CD 133+ cell grafts in stroke. Crown Copyright (c) 2005 Published by Elsevier B.V. All rights reserved.

引用

页码：116 / 122

页数：7

共 26 条

[1]

*AM HEART ASS, 2004, AM HEART ORG, V13

[2] Central nervous system entry of peripherally injected umbilical cord blood cells is not required for neuroprotection in stroke [J].